The board of directors (the "Board") of CSPC Pharmaceutical Group Limited announced that the Investigational New Drug (IND) application for JMT106 (the "Product"), a bispecific fusion protein drug developed by the Group, has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trial in the U.S. The Product is an anti-tumor drug. The indication for this clinical trial approval is GPC3-positive solid tumors. The Product is a bispecific fusion protein drug that targets GPC3 and interferon receptors, killing tumor cells through GPC3-targeted antibodies and simultaneously activating the immune regulation of the tumor microenvironment mediated by interferon receptors. GPC3 is specifically and highly expressed in various solid tumors such as hepatocellular carcinoma, squamous cell carcinoma of the lung and ovarian cancer. Preclinical studies have demonstrated that the Product
has a broad variety of indications, showing significant anti-tumor effects in malignant tumor models, such as liver cancer, lung cancer and ovarian cancer, as well as good safety profile, which provides a promising clinical development value.